bbchien
Touchdown! Greaser!
Reciveved today:
Effective April 24, 2024, three additional medications will be allowed for special issuance consideration:
duloxetine (Cymbalta), venlafaxine (Effexor), and desvenlafaxine (Pristiq). They represent the addition of a new class of anti-depressant medications i.e., serotonin-norepinephrine reuptake Inhibitors (SNRIs). Initially, all existing policies for the Anti-depressant/SSRI program will still apply. The AME Guide will be updated on April 24, 2024.
Effective April 24, 2024, three additional medications will be allowed for special issuance consideration:
duloxetine (Cymbalta), venlafaxine (Effexor), and desvenlafaxine (Pristiq). They represent the addition of a new class of anti-depressant medications i.e., serotonin-norepinephrine reuptake Inhibitors (SNRIs). Initially, all existing policies for the Anti-depressant/SSRI program will still apply. The AME Guide will be updated on April 24, 2024.